The Safety and Effectiveness of Zidovudine in the Treatment of HIV-Infected Children With Mild to Moderate Symptoms
Status:
Completed
Trial end date:
1992-09-01
Target enrollment:
Participant gender:
Summary
To determine the safety and usefulness of zidovudine (AZT) for the treatment of children 3
months to 12 years of age. This study is designed to determine if children who are infected
with HIV and who have a special type of lung disease called lymphocytic interstitial
pneumonitis (LIP) or other early symptoms of HIV infection may derive benefit from treatment
with AZT. It is hoped that this drug will prevent children from developing additional
symptoms and infections and will help resolve already existing symptoms.
AZT has been shown in the laboratory to inhibit the infection of cells by HIV. AZT has been
shown to decrease the mortality and the frequency of opportunistic infections in certain
adult patients with symptomatic HIV infection. It is, therefore, likely that symptomatic
HIV-infected children may also benefit from specific antiviral therapy.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)